Risk factors

Savara (SVRA) risk factors

Item 1A of every Savara Inc. 10-K on file, and what changed from one year to the next.

Open SVRA in Gloomberb →
  • FY2025 10-K risk factors

    44 risks, 3 new, 2 dropped, 7 reworded since the prior year. Savara updated debt obligations with a new Hercules Capital loan facility and expanded data privacy and healthcare compliance disclosures.

    Filed Mar 13, 2026
  • FY2024 10-K risk factors

    43 risks. Savara relies entirely on the clinical, regulatory, and commercial success of its sole product candidate, MOLBREEVI, for aPAP. The company faces significant risks regarding capital requirements, regulatory approvals, third-party reimbursement, and lack of issued patents for MOLBREEVI.

    Filed Mar 27, 2025